Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Voluntary Filers Current Fiscal Year End Date Entity Well Known Seasoned Issuer Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity Public Float Document Annual Report Document Transition Report Document Fin Stmt Error Correction Flag Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Icfr Auditor Attestation Flag Auditor Name Auditor Location Auditor Firm Id Local Phone Number Security 12g Title Entity Interactive Data Current CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] ASSETS Current assets: Cash Accounts receivable, net Grant receivable Inventory Prepaid expenses Total current assets [Assets, Current] Property and equipment, net Right to use assets Other assets: Intangible assets, net Goodwill Deposits, long term Total other assets [Other Assets] Total assets [Assets] LIABILITIES AND DEFICIT Current liabilities: Accounts payable and accrued expenses, including related party payables of $1,271,685 and $1,349,465, respectively Deferred revenue, grant Lease liability, short term Notes payable, net of debt discount of $0 and $41,452, respectively Notes payable, related parties, net of debt discount of $0 Total current liabilities [Liabilities, Current] Long term liabilities: Economic Injury Disaster loan, long term Royalty obligation, net of discount of $3,941,262 and $4,418,698, related parties Upfront purchase price liability Royalty liability Lease liability, long term Total liabilities [Liabilities] Commitments and contingencies Deficit: Preferred stock, value Common stock, $0.001 par value; 750,000,000 shares authorized, 24,489,311 and 13,299,349 shares issued and outstanding as of December 31, 2025 and 2024, respectively Common stock subscribed Additional paid in capital Accumulated deficit Total deficit attributable to BioCorRx, Inc. [Equity, Attributable to Parent] Non-controlling interest Total deficit [Equity, Including Portion Attributable to Noncontrolling Interest] Total liabilities and deficit [Liabilities and Equity] Convertible Series A Preferred Stock [Member] Convertible Series B Preferred Stock [Member] Related party payables Debt discount on notes payable Related party debt discount on notes payable Discount on Royalty obligation related parties Preferred Stock, Shares Authorized Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Preferred Stock, Shares Designated Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Revenues, net Operating expenses: Cost of implants and other costs Research and development Selling, general and administrative Depreciation and amortization Total operating expenses [Operating Expenses] Loss from operations [Operating Income (Loss)] Other income (expenses): Interest expense - related parties [Interest expense - related parties] Interest expense, net [Interest Expense, Operating and Nonoperating] Loss on settlement of debt Grant income Change in fair value of upfront purchase price liability Change in fair value of royalty liability Other miscellaneous income Total other (expenses) income, net [Nonoperating Income (Expense)] Loss before provision for income taxes [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Income taxes Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Non-controlling interest [Net Income (Loss) Attributable to Noncontrolling Interest] Net loss attributable to BioCorRx Inc. [Net Income (Loss) Attributable to Parent] Net loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted CONSOLIDATED STATEMENTS OF DEFICIT Equity Components [Axis] Series A Convertible Preferred Stocks Series B Convertible Preferred Stock Common Stock Common Stock Subscribed Additional Paid-In Capital Accumulated Deficit Noncontrolling Interest Balance, shares [Shares, Issued] Balance, amount Common stock issued for services rendered, shares Common stock issued for services rendered, amount Common stock issued in connection with issuance of promissory notes, shares Common stock issued in connection with issuance of promissory notes, amount Warrants issued in connection with issuance of promissory notes Common stock issued in connection with subscription agreement, shares Common stock issued in connection with subscription agreement, amount Common stock issued in connection with conversion of promissory notes and accounts payable, shares Common stock issued in connection with conversion of promissory notes and accounts payable, amount Share-based compensation Imputed interest for related party advances Net loss Common stock issued in connection with exercise of warrants, shares Common stock issued in connection with exercise of warrants, amount Common stock issued in connection with APA (Note 4), shares Common stock issued in connection with APA (Note 4), amount Warrants issued in connection with APA (Note 4) Warrants issued in connection with the Sales Representative Agreement Balance, shares Balance, amount CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to cash flows used in operating activities: Depreciation and amortization [Depreciation, Depletion and Amortization] Amortization of discount on royalty obligation Amortization of debt discount Amortization of right-of-use asset Loss on settlement of debt Change in fair value of upfront purchase price liability [Change in fair value of upfront purchase price liability] Change in fair value of royalty liability Other income [Other Income] Stock based compensation Imputed interest for related party advances Warrants issued in connection with the Sales Representative Agreement [Warrants issued in connection with the Sales Representative Agreement] Changes in operating assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Grant receivable [Increase (Decrease) in Other Receivables] Inventory [Increase (Decrease) in Inventories] Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued expenses Deposits Upfront purchase price liability [Upfront purchase price liability] Lease liability Deferred revenue Deferred revenue, grant [Deferred revenue, grant] Net cash used in operating activities [Cash Provided by (Used in) Operating Activity, Including Discontinued Operation] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from common stock subscription and royalty agreement Payment to Economic Injury Disaster loan [Payment to Economic Injury Disaster loan] Payment of notes payable - related party [Repayments of Related Party Debt] Payment of notes payable [Payment of notes payable] Proceeds from notes payable Proceeds from notes payable - related party Net cash provided by financing activities [Cash Provided by (Used in) Financing Activity, Including Discontinued Operation] Net increase (decrease) in cash [Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation] Cash, beginning of the year Cash, end of the year Supplemental disclosures of cash flow information: Interest paid Taxes paid Supplemental Noncash investing and financing activities Common stock issued in connection with issuance of promissory notes Common stock issued in connection subscription agreement Record right to use assets per ASC 842 Record lease liability per ASC 842 Common stock issued in connection with APA (Note 4) Warrants issued in connection with APA (Note 4) [Warrants issued in connection with APA (Note 4)] Common stock issued in connection with conversion of promissory notes and accounts payable Derivative liability recognized in connection with issuance of promissory notes Warrants issued in connection with issuance of promissory notes [Warrants issued in connection with issuance of promissory notes] Insider Trading Arragements Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non Rule 10b5-1 Arrangement Adopted [Flag] Non Rule 10b5-1 Arrangement Terminated [Flag] Insider Trading Policy [Text Block] BUSINESS BUSINESS Business Description and Basis of Presentation [Text Block] SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] GOING CONCERN AND MANAGEMENTS LIQUIDITY PLANS GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS BUSINESS COMBINATION BUSINESS COMBINATION Business Combination [Text Block] PREPAID EXPENSES PREPAID EXPENSES Other Current Assets [Text Block] PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] LEASE LEASE Leases of Lessee Disclosure [Text Block] INTANGIBLE ASSETS INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] ACCOUNTS PAYABLE AND ACCRUED EXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] NOTES PAYABLE NOTES PAYABLE Debt Disclosure [Text Block] NOTES PAYABLERELATED PARTIES NOTES PAYABLE-RELATED PARTIES ECONOMIC INJURY DISASTER LOAN ECONOMIC INJURY DISASTER LOAN [ECONOMIC INJURY DISASTER LOAN] ROYALTY OBLIGATIONS NET ROYALTY OBLIGATIONS, NET STOCKHOLDERS EQUITY (DEFICIT) STOCKHOLDERS' EQITY /(DEFICIT) STOCK OPTIONS AND WARRANTS [STOCK OPTIONS AND WARRANTS] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] CONCENTRATIONS CONCENTRATIONS Concentration Risk Disclosure [Text Block] NON-CONTROLLING INTEREST COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] SEGMENT INFORMATION SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] CONTINGENT PAYMENT CONTINGENT PAYMENT [CONTINGENT PAYMENT] INCOME TAXES INCOME TAXES Income Tax Disclosure [Text Block] REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS Condensed Financial Statements [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] Basis of Presentation Revision of Previously Issued Interim Financial Statements Revenue Recognition Deferred Revenue-Grant Use of Estimates Accounts Receivable Inventory Inventory, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value Measurements Business Combinations and Contingent Consideration Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Segment Information Long-Lived Assets Intangible Assets Property and Equipment Leases Net (loss) Per Share Advertising Grant Income Research and development costs Stock Based Compensation Income Taxes Variable Interest Entity Non-Controlling Interest Royalty Obligations, net Recent Accounting Pronouncements Schedule of net sales Schedule of Inventory Schedule of antidilutive securities Schedule of assets acquired and liabilities Schedule of assumptions used for fair value of warrant Schedule of fair value of the identifiable intangible assets Schedule of pro forma financial information Schedule of prepaid expenses Schedule of property and equipment Schedule of lease liability Schedule of maturity of lease agreements Schedule of lease cost Schedule of Weighted-average remaining lease term Schedule of Intangible Assets Schedule of future amortization of patents Schedule of future amortization of customer base Schedule of accounts payable and accrued expenses Schedule of outstanding notes payable Schedule of outstanding notes payable related party Schedule of future principle payments Scheule of Black-Scholes option pricing model assumptions used Schedule of stock options activity Schedule of information regarding stock options Schedule of assumptions in warrants under black scholes option pricing model Schedule of changes in warrants outstanding and the related prices Summary of warrant activity Schedule of net loss attributable to non-controlling interest Schedule of changes in non-controlling interest Schedule of Segment Reporting income or loss and total assets Schedule of contingent payments Components of the income tax provisions Schedule of different tax rate Schedule of deferred taxes Schedule of condensed consolidated balance sheet Schedule of condensed consolidated statements of operations Schedule of condensed consolidated statements of deficit Schedule of condensed consolidated statement of cash flows Related and Nonrelated Parties [Axis] BioCorRx Pharmaceuticals, Inc [Member] Management fee Ownership retained percent Sales/access fees Distribution rights income Membership/program fees Supply and distribution sales Net sales Raw materials Work in process Finished goods Inventory Shares underlying options outstanding Shares underlying warrants outstanding Convertible preferred stock outstanding Total [Weighted Average Number of Shares Outstanding, Diluted, Adjustment] Exercise Price Range [Axis] Minimum [Member] Maximum [Member] Allowance for doubtful accounts Advertising costs Grant funding during the first year Grant funding Grant funding during the second year Grant funding during the third year Grant additional funding during the third year Grant receivables Deferred revenues related to grant Grant income [Grant income] Research and development expenses Ownership percentage Royalty obligations description Description of Non-Controlling Interest Royalty obligations, net Property plant and equipment estimated useful lives Award Type Axis Plan Name Axis Investment Type Axis Related Party Transaction [Axis] Award Date [Axis] February 22, 2024 [Member] Unsecured Promissory Note Related Third Party [Member] Investors [Member] Thomas Welch [Member] March 8, 2024 [Member] March 25, 2024 [Member] Q4 Exchange Agreement [Member] October 24, 2025 [Member] Mr Lucido [Member] 2025 Q3 SPA [Member] 2025 Q4 SPA [Member] 2025 Q4 Subscription Agreement [Member] Thomas 2025 Exchange Agreement [Member] Working capital deficit Cash [Cash] Common stock price per share Lump sum payment of amortization Net cash used in operating activities Gross Proceeds Conversion price Exercise price of warrants maximum Exercise price of warrants minimum Debt conversion, description Promissory note outstanding Common stock shares issued Professional fees Upfront purchase price Retention description Common stock purchase Exercise price [Class of Warrant or Right, Exercise Price of Warrants or Rights] Description of funding Award granted by third party Convertible conversion price decrease Convertible conversion price increase Debt instrument term Exercise price [Stock Option, Exercise Price, Decrease] Proceeds from notes payable Restricted stock shares issued Interest rate Restricted stock price per share Restricted stock value Shares of common stock issued in exchange Repayment of debt principal payments Outstanding debt balance Issued warrant to purchase common stock Interest payable Price per share Debt instrument lum sum payment Outstanding consulting fees Debt instrument maturity start date Debt instrument maturity end date Amendment description Purchase price Total gross proceeds from issuance of common stock Initial tranche os shares issued Cash proceeds from warrants Gross Proceeds [Gross Proceeds] Exercise price Upfront purchase price [Upfront purchase price] Royalty payments Stock consideration Warrant consideration Total [Business Combination, Contingent Consideration, Liability] Inventories Trademarks (included in intangibles) Customer base (included in intangibles) Other payable [Business Combination, Recognized Liability Assumed, Other Liability, Current] Total identifiable net assets Goodwill Risk-free interest rate Expected term (years) Expected volatility Expected dividends Indefinite-Lived Intangible Assets [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Trademarks [Member] Customer Base [Member] Estimated useful life Trademarks (included in intangibles) Customer base (included in intangibles) Total revenue Net loss [Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax] Pro forma revenue Pro forma earnings Retention description Common stock shares issued Closing market price Common stock purchase Exercise price Fair value of stock issued Royalty payments Upfront purchase price Discounted at the risk-free rate Discounted at required metric risk premium Acquisition-related costs Pro forma adjusted amount Prepaid insurance Prepaid subscription services Total Property Plant And Equipment By Type Axis Office Equipment [Member] Computer Equipment [Member] Manufacturing Equipment [Member] Leasehold improvement [Member] Property and equipment, gross Less accumulated depreciation [Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment] Property and equipment, net Depreciation expense Total lease liability Less: short term portion Long term portion 2026 2027 2028 2029 and beyond Subtotal Less: present value discount Lease liability [Lease liability] Operating lease expense Total lease expense Weighted-average remaining lease term Lease Contractual Term [Axis] Lease Agreement [Member] Maximum [Member] Minimum [Member] Right to use assets and lease liability Total lease expense [Operating Leases, Rent Expense] Monthly lease payments Right to use assets and lease liability [Right-of-Use Asset Obtained in Exchange for Operating Lease Liability] Expiry date Short-Term Debt, Type [Axis] Promissory note payable one Promissory note payable two Promissory note payable three Promissory note payable four Promissory note payable five Promissory note payable six Promissory note payable seven Advances from third party Total Outstanding notes payable Total Outstanding notes payable Debt instrument due date Debt discount, net September 9, 2021 [Member] Third Party [Member] October 6, 2022 [Member] January 25, 2023 [Member] September 6, 2023 [Member] November 10, 2023 [Member] December 8, 2023 [Member] March 14 2024 [Member] Interest rate during period Interest rate increased Advances from a third party Interest payable on note payable Unsecured promissory note payable Promissory Notes payable Interest rate Promissory note issued Issued warrant to purchase common stock Price per share Interest payable Outstanding debt balance Shares of common stock issued in exchange Debt instrument maturity end date Debt instrument maturity start date Debt instrument lum sum payment Repayment of debt principal payments Restricted stock price per share Restricted stock value Restricted stock shares issued Debt extinguishment loss Share-Based Payment Arrangement, Plan Modification, Incremental Cost Share-Based Payment Arrangement, Plan Modification, Incremental Cost, shares Exercise price Convertible conversion price increase Share-Based Payment Arrangement, Plan Modification, Incremental Cost [Share-Based Payment Arrangement, Plan Modification, Incremental Cost] Conversion price Outstanding balance Convertible conversion price decrease Interest Expense, Debt Debt Instrument, Per Share Warrant issued Interest payment Notes payable, net of debt discounts Derivative liability and debt discount Common stock issued Common stock issued, value Common stock price per shares Common stock value Debt discount interest expense 2026 [Capital Leases, Future Minimum Payments Receivable, Next Rolling 12 Months] 2027 [Capital Leases, Future Minimum Payments Receivable, Rolling Year Two] 2028 [Capital Leases, Future Minimum Payments Receivable, Rolling Year Three] 2029 2030 and after Total [Capital Leases, Future Minimum Payments Receivable] July 17, 2020 [Member] Economic Injury Disaster Loan assistance program [Member] April 28, 2020 [Member] Accumulated interest on EIDL Loan Balance of principal and interest payable (Period) description Proceeds from EIDL loan Interest rate Payments of interest Monthly payments of principal and interest Advances from SBA Joseph Galligan [Member] Interest expense amortization Non-cash interest expense Expected life of the arrangement Royalty agreements description Ownership percentage Financial Instrument [Axis] Option [Member] Risk-free interest rate [Risk-free interest rate] Expected term (years) [Expected term (years)] Expected volatility [Expected volatility] Expected dividends [Expected dividends] Number of Shares Outstanding, Beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number] Expired [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period] Grants [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures] Outstanding, Ending Exercisable at Ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number] Weighted Average Exercise Price Outstanding, Beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Expired [Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price] Grants Outstanding, Ending Exercisable at Ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price] Weighted Average Remaining Contractual Term Outstanding, Beginning [Outstanding, Beginning] Grants [Grants] Outstanding at Ending Exercisable at Ending [Exercisable at Ending] Aggregate Intrinsic Value Outstanding, Beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding] Outstanding at Ending Exercisable at Ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value] Options Exercisable [Member] 0.01-2.50 [Member] 2.51-5.00 [Member] 5.01 And Up [Member] Options Outstanding [Member] Exercisable, Number of Options Weighted average remaining life in years Number of options Class Of Warrant Or Right Axis Warrants [Member] Risk-free interest rate Expected term (years) [Expected term (years) 1] Expected volatility Expected dividends Warrants Outstanding [Member] Warrants Exercisable [Member] 0.89 [Member] Weighted average remaining life in years Exercisable, Number of Options Exercise price [Warrant, Exercise Price, Increase] Number of outstanding Warrants [Member] Granted Exercise Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercise Weighted Average Exercise Price, Expired 2014 Equity Incentive Plan [Member] Consultant [Member] 2016 Equity Incentive Plan [Member] 2018 Equity Incentive Plan [Member] 2022 Equity Incentive Plan [Member] Alpha [Member] Third Parties [Member] Stock price Stock compensation expense Proceeds from issuance of common stock Description of warrants Common stock shares sold Description of third amendment agreement Purchase of common stock, shares Common stock shares issued [Conversion of Stock, Shares Issued] Warrants to purchase shares of common stock Exercise price [Stock Option, Exercise Price, Increase] Aggregate total Percent of issued and outstanding shares Stock option Issued warrant to purchase common stock Price per share Outstanding debt balance Shares of common stock issued in exchange Purchase price Title and Position [Axis] Consolidated Entities [Axis] Director [Member] BioCorRx Pharmaceuticals [Member] Compensation and interest payable Ownership retained percent Management fee Concentration Risk Benchmark [Axis] Sales Revenue [Member] Six Customers [Member] Two Customers [Member] Accounts Receivable [Member] Concentration risk, percentage Accounts receivable, net [Accounts Receivable, after Allowance for Credit Loss] Board of directors Orange County Research Center [Member] Pellecome [Member] Charles River Laboratories, Inc. [Member] Alpine Creek [Member] BICX Holding Company LLC [Member] January 5, 2024 [Member] Renumeration amount Issue of common stock to consultant Payment of clinical services Attorney's fees Attorney's fees received or awarded Settelment amount Interest rate [Interest rate] Annual compensation Cash received Stock equivalent amount Compensation for services, description Outstanding payable Remaining commitment Royalty due Total consideration amount Payables to Alpine Creek Paid to Alpine Creek Payable commitment description Payable per treatment sold Profit holding percentage Common stock issued upon convertible debt Convertible Promissory Note Total Interest Payment Conversion agreement description Research and development Selling, general and administrative Fair value on the acquisition date Upfront Purchase price Payments upfront purchase price Change in fair value upfront purchase price Fair value upfront purchase price Fair value on the acquisition date Royalty Payment Payments of royalty payment Change in fair value Royalty Payment Fair value royalty payment Net sales and profit sharing Upfront purchase price [Upfront purchase price 1] Seller for purchase of assets description Royalty payments period Current provision: Federal State Provision at statutory rate State taxes, net of federal benefit Other Interest addback Nondeductible and other items Change in valuation allowance Total [Effective Income Tax Rate Reconciliation, Tax Credit, Percent] Deferred tax assets: Stock options issued for services Net operating loss carry forwards Section 174 capitalization Accrual to cash Royalty obligation Change in fair value of royalty liability [Change in fair value of royalty liability] Chang in fair value of upfront purchase price liability Other [Deferred Tax Assets, Other] Total deferred tax assets Royalty obligation [Royalty obligation] Right to use assets [Right to use assets] Total deferred tax liabilities [Deferred Tax Liabilities, Gross] Deferred tax net Valuation allowance [Deferred Tax Assets, Valuation Allowance] Net deferred tax assets Income Tax Jurisdiction [Axis] Federal [Member] State [Member] Federal income tax rate Net operating loss carryforwards Cumulative change in ownership Federal net operating losses carryforward description Patents [Member] Intangible assets, gross Less accumulated amortization [Finite-Lived Intangible Assets, Accumulated Amortization] Intangible assets, net [Finite-Lived Intangible Assets, Net] Customer 2026 [Finite-Lived Intangible Asset, Expected Amortization, Year One] 2027 [Finite-Lived Intangible Asset, Expected Amortization, Year Two] 2028 [Finite-Lived Intangible Asset, Expected Amortization, Year Three] 2029 [Finite-Lived Intangible Asset, Expected Amortization, Year Four] 2030 and after [2030 and after] Total future amortization of the patents Naltrexone Implant Formulation [Member] Australia from Trinity Compound Solutions [Member] Accumulated amortization Amortization expense Patent acquired Estimated useful lives Accumulated amortization Business combination, intangible assets acquired Accounts payable Interest payable on notes payable Interest payable on notes payable, related parties Deferred insurance Accrual of interest and loss on contingency Interest payable on EIDL loan Line of Credit Accrual of interest on unpaid upfront purchase price Accrued expenses Account payable accrued expenses Kent Emry [Member] Louis C Lucido [Member] Lourdes Felix [Member] Advances from related parties Outstanding notes payables to related parties Notes payable to related parties September 2022 [Member] Louis Lucido [Member] 2025 [Member] Interest expense - related parties [Interest expense - related parties 1] Promissory note outstanding Outstanding balance advances Professional fees Accrued interest Interest expense amortization Due to related party Unsecured promissory notes Fair value of warrant Imputed interest Imputed interest rate Interest rate during period Outstanding balance [Outstanding balance] Unsecured promissory note payable Interest rate [Debt Conversion, Converted Instrument, Rate] Conversion price Advances Debt discount Common share purchase Interest payable Notes payable Accumulated interest notes Payable Due from related party Principal payments (monthly) Outstanding principal balance on issuance of promissory note Warrant issue Common stock value Joseph DeSanto MD [Member] Average Non-controlling interest percentage of profit/losses Net loss attributable to the non-controlling interest Beginning Balance Net loss attributable to the non-controlling interest Ending Balance Ownership percentage held by company Descirption of management services agreement Ownership percentage held by former officers Extinguishment of Debt [Axis] Promissory Note [Member] Related Party [Member] Common Stocks [Member] Q4 Lucido Subscription Agreement [Member] Board of Directors [Member] Convertible promissory notes [Member] Convertible accounts payable [Member] Securities Purchase Agreement [Member] One Related Party [Member] Q3 Lucido Subscription Agreement [Member] Preferred stock, shares authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Preferred stock, shares issued Preferred stock, shares outstanding Description of convertible preferred stock Common stock were issued Proceeds from common stock subscription and royalty agreement Common share issued for services, shares Common share issued for services, value Common share issued for compensation, shares Common share issued for compensation, value Common share issued for conversion of promissory notes Common share issued for promissory notes, shares Common share issued for promissory notes, value Debt converted into equity Conversion of related party advances into equity Additional issuance of share Director fees Accrued interest Price per shares Common share issued for conversion of director fee, shares Common share issued for conversion of director fee, value Outstanding principal balance on exchange of promissory note Accounts payable Gain on settlement of debt Share outstanding amount Common stock issued for debt conversion, Value Interest payable Revision of Prior Period [Axis] Series A Convertible Preferred Stock [Member] As Revised [Member] Revision [Member] Series A Convertible Preferred Stock [Member] As Reported [Member] ASSETS Current assets: Cash Accounts receivable, net Grant receivable Inventory Prepaid expenses Total current assets Property and equipment, net Right to use assets Other assets: Intangible assets, net Goodwill Deposits, long term Total other assets Total assets LIABILITIES AND DEFICIT Current liabilities: Accounts payable and accrued expenses Deferred revenue-grant Lease liability, short term Notes payable, related parties, net of debt discount Total current liabilities Long term liabilities: Economic Injury Disaster loan, long term [Other Long-Term Debt, Noncurrent] Upfront purchase price liability Royalty liability Royalty obligation, net of discount Lease liability, long term Total liabilities Commitments and contingencies Deficit: Preferred stock, no par value, 600,000 authorized Common stock subscribed Common stock subscription receivable [Common Stock, Share Subscribed but Unissued, Subscriptions Receivable] Common stock subscription receivable Additional paid in capital Accumulated deficit Total deficit attributable to BioCorRx, Inc. Non-controlling interest Total deficit Total liabilities and deficit As Revised [Member] Revision [Member] Revenues, net Operating expenses: Cost of implants and other costs Selling, general and administrative Depreciation and amortization [Depreciation, Amortization and Accretion, Net] Total operating expenses Loss from operations Other income (expenses): Loss on settlement of debt Grant income Change in fair value of upfront purchase price liability Change in fair value of royalty liability Other miscellaneous income [Other miscellaneous income] Total other income (expenses) Net loss before provision for income taxes Income taxes NET LOSS ATTRIBUTIBLE TO BIOCORRX, INC. Net loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted Accumulated Deficit Reported [Member] Noncontrolling Interest Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock Common Stock Subscribed Additional Paid-In Capital Common Stock Subscription Receivable Common stock issued for services rendered, amount Common stock issued in connection with subscription agreement, amount Common stock issued in connection with conversion of promissory notes and accounts payable amount Common stock issued in connection with exercise of options, amount Share-based compensation [Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture] Imputed interest for related party advances Common stock issued for services rendered, shares Common stock issued in connection with subscription agreement, shares Common stock issued in connection with conversion of promissory notes and accounts payable [Common stock issued in connection with conversion of promissory notes and accounts payable] Common stock issued in connection with exercise of options, shares Balance Shares [Balance Shares] Balance, Shares CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to cash flows used in operating activities: Depreciation and amortization [Other Depreciation and Amortization] Amortization of discount on royalty obligation Amortization of debt discount Amortization of right-of-use asset Change in fair value of upfront purchase price liability Stock based compensation Fair value of options issued Changes in operating assets and liabilities: Grant receivable [Grant receivable] Other receivable Inventory [Inventory] Accounts payable and accrued expenses Upfront purchase price liability Lease liability Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of common stock Proceeds from common stock subscription and royalty agreement Payment to EIDL loan [Payment to EIDL loan] Proceeds from notes payable - related party Net cash provided by financing activities Net increase in cash Supplemental disclosures of cash flow information: Interest paid Taxes paid Common stock issued in connection with conversion of promissory notes and accounts payable [Common stock issued in connection with conversion of promissory notes and accounts payable 1] Common stock issued in connection with exercise of warrants Common stock issued for services rendered Common stock issued in connection with APA (Note 4) [Common stock issued in connection with APA (Note 4)] Warrants issued in connection with APA (Note 4) [Warrants issued in connection with APA (Note 4) 1] Common stock issued in connection with issuance of promissory notes [Common stock issued in connection with issuance of promissory notes] Subsequent Event Type [Axis] Subsequent Event [Member] Board Of Directors [Member] Purchase shares of Common Stock Aggregate purchase price amount The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.